P815: HIGH VALENCY OF IGM-2644, A CD38XCD3 IGM BISPECIFIC T CELL ENGAGER, DISPLACES DARATUMUMAB BINDING AND INDUCES POTENT MULTIPLE MYELOMA CELL KILLING
Main Authors: | Kevin C. Hart, Daniel Santos, Deepal Pandya, Rong Deng, Keyu LI, Yinghui Guan, Genevive Hernandez, Thomas Manley, Maya K. Leabman, Paul R. Hinton, Liqin Liu, Angus M. Sinclair, Albert F. Candia, Stephen F. Carroll, Bruce A. Keyt, Maya F. Kotturi |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-08-01
|
Series: | HemaSphere |
Online Access: | http://journals.lww.com/10.1097/01.HS9.0000970164.63056.5c |
Similar Items
-
P1276: DOSE RESPONSE PROFILE OF IGM-2323, A CD20XCD3 IGM BISPECIFIC T CELL ENGAGER, IN TRANSLATIONAL MODELS SUPPORTS PHASE 2 DOSE SELECTION IN NON-HODGKIN’S LYMPHOMA
by: M. K. Leabman, et al.
Published: (2022-06-01) -
1174 Costimulatory IgM T-cell engagers with enhanced and durable cytotoxicity
by: Yue Wang, et al.
Published: (2023-11-01) -
1078 Agonistic CD40 IgM antibodies enhance immune responses beyond that of IgGs
by: Umesh Muchhal, et al.
Published: (2023-11-01) -
Structure, Function, and Therapeutic Use of IgM Antibodies
by: Bruce A. Keyt, et al.
Published: (2020-10-01) -
711 IGM-7354 is an anti-PD-L1 IgM antibody and IL-15 cytokine fusion that enhances NK and CD8+ T cell proliferation and tumor cytotoxicity plus potently reverses T cell exhaustion
by: Maya Kotturi, et al.
Published: (2021-11-01)